GlassScriptPhysician profile
Amarilis Torres
NPI 1003927500
$19,700.96
in general payments reported to CMS, 2019-2025
32 companies · $1,728 in 2025
The $1,728 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,829 · 2020: $2,505 · 2021: $3,079 · 2022: $3,153 · 2023: $3,416 · 2024: $2,991 · 2025: $1,728.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,966 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,966.43 |
| Education | $168.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,494.73 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Ucb, INC. | $2,621.37 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,708.03 | 2019-2025 | |
| Amgen INC. | $1,688.56 | 2019-2025 | Enbrel, Evenity, Otezla |
| Novartis Pharmaceuticals Corporation | $1,666.41 | 2019-2024 | |
| Genzyme Corporation | $1,404.91 | 2019-2025 | |
| Janssen Biotech, INC. | $973.46 | 2019-2025 | Tremfya |
| Genentech USA, INC. | $969.57 | 2019-2024 | Actemra, Rituxan |
| Glaxosmithkline, LLC. | $684.96 | 2021-2025 | Benlysta, Nucala |
| Fresenius Kabi USA, LLC | $531.04 | 2023-2025 | Idacio, Tyenne |
| Radius Health, INC. | $509.38 | 2019-2025 | Tymlos |
| Lilly USA, LLC | $428.96 | 2019-2023 | Taltz, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $401.97 | 2019-2025 | Orencia |
| Mallinckrodt Hospital Products INC. | $317.64 | 2020-2024 | Acthar |
| Sobi, INC | $279.67 | 2019-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $224.25 | 2023-2025 | Hadlima, Renflexis |
| Ani Pharmaceuticals, INC. | $195.14 | 2022-2024 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.21 | 2019-2024 | Cyltezo |
| Mallinckrodt Enterprises LLC | $87.97 | 2019 | |
| Horizon Therapeutics Plc | $73.11 | 2019-2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $60.05 | 2020-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $50.96 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $40.32 | 2021-2023 | |
| Aurinia Pharma U.S., INC. | $33.32 | 2021-2024 | Lupkynis |
| Actelion Pharmaceuticals US, INC. | $25.23 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $24.96 | 2022 | |
| Sandoz INC. | $17.19 | 2024 | Hyrimoz |
| Ibsa Pharma INC. | $15.23 | 2020 | |
| Fidia Pharma USA INC. | $13.28 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.25 | 2022 | |
| Bioventus LLC | $11.61 | 2019 | |
| Medexus Pharma, INC. | $11.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amarilis Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.